Literature DB >> 6370168

Clostridium difficile. Colonization and toxin production in a cohort of patients with malignant hematologic disorders.

J G Morris, W R Jarvis, O L Nunez-Montiel, M L Towns, F S Thompson, V R Dowell, E O Hill, W R Vogler, E F Winton, J M Hughes.   

Abstract

We examined 45 (80%) of 56 consecutive adult patients with malignant hematologic disorders who were hospitalized during a 15-week period at Emory University Hospital, Atlanta. Stool samples for Clostridium difficile culture and cytotoxin assay were obtained on admission and then weekly during each patient's hospitalization. On admission, four patients had detectable C difficile in their stool samples, which was associated with prior antimicrobial use but not with prior cancer chemotherapy. One of the four patients with positive stool samples also had toxin present in the stool sample and was the only one with diarrhea. Eight (36%) of 22 patients hospitalized for one or more weeks had C difficile isolated from at least one stool specimen. The positive cultures showed no clustering in time, and no risk factors were identified for colonization. Only seven of 15 culture-positive stool samples and three of seven toxin-positive samples were associated with diarrhea.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370168     DOI: 10.1001/archinte.144.5.967

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  Clostridium difficile in an oncology unit.

Authors:  A L Brunetto; A D Pearson; A W Craft; S J Pedler
Journal:  Arch Dis Child       Date:  1988-08       Impact factor: 3.791

2.  Differential yield of pathogens from stool testing of nosocomial versus community-acquired paediatric diarrhea.

Authors:  S Deorari; A McConnell; K K Tan; N Jadavji; D Ma; D Church; G Katzko; D G Gall; T Jadavji; H D Davies
Journal:  Can J Infect Dis       Date:  1999-11

Review 3.  Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis.

Authors:  Ioannis M Zacharioudakis; Fainareti N Zervou; Elina Eleftheria Pliakos; Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

4.  Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients.

Authors:  David B Stewart; Emmanuel Yacoub; Junjia Zhu
Journal:  J Gastrointest Surg       Date:  2012-06-13       Impact factor: 3.452

5.  Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains.

Authors:  S R Heard; B Wren; M J Barnett; J M Thomas; S Tabaqchali
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

6.  High prevalence of Clostridium difficile diarrhoea during intensive chemotherapy for disseminated germ cell cancer.

Authors:  H Nielsen; G Daugaard; M Tvede; B Bruun
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

Review 7.  Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications.

Authors:  Luis Furuya-Kanamori; John Marquess; Laith Yakob; Thomas V Riley; David L Paterson; Niki F Foster; Charlotte A Huber; Archie C A Clements
Journal:  BMC Infect Dis       Date:  2015-11-14       Impact factor: 3.090

Review 8.  Clostridium difficile - From Colonization to Infection.

Authors:  Holger Schäffler; Anne Breitrück
Journal:  Front Microbiol       Date:  2018-04-10       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.